ReNerve (ASX:RNV), an Australian medical device innovator specialising in peripheral nerve injury solutions, has secured broader listing approval for its NervAlign Nerve Cuff in Hong Kong, granting full access to both public and private hospital systems, including facilities in the Greater Bay Area.
The approval followed an independent review of clinical data, which confirmed the device's safety and effectiveness in supporting nerve repair and post-surgery recovery.
ReNerve, which markets the NervAlign Nerve Cuff in the US, Bahrain, New Zealand, Hong Kong, and Thailand, said the positive assessment strengthens its case for regulatory approvals in additional markets, including Europe.
"This approval not only expands our marketing reach in Asia but also validates, through independent government review, the clinical benefits our device provides," said Dr Julian Chick, CEO of ReNerve.
The NervAlign Nerve Cuff is recognised as a significant advancement in peripheral nerve repair, offering clinicians a precise tool to support nerve regeneration and patient recovery following injury or surgery.
At the time of reporting, ReNerve's share price was $0.12.